Psilocybin for Depression: What the Research Shows in 2026

Why psilocybin is a different kind of antidepressant

Most antidepressants, including SSRIs like Prozac and Zoloft, are taken daily for months or years. They can take several weeks to work, many people do not respond well to the first one they try, and side effects such as emotional numbness and sexual problems lead many people to quit.

Psilocybin flips that model. Patients receive one or two doses in a clinic, with trained staff present for the full session. Improvements often show up within a day or two and, for many patients, persist for months. Researchers think this is because psilocybin temporarily opens the brain to change, rather than adjusting its chemistry day after day. Our guide to what shrooms do to your brain covers the mechanism.

The key trials, in order

The Phase 3 results that changed everything

Phase 3 trials are the large, rigorous studies the FDA relies on to approve a drug. Compass Pathways ran two of them for COMP360, its synthetic psilocybin, in people with treatment-resistant depression (TRD).

The patients were hard to treat. In COMP006, participants had been in their current depressive episode for more than three years on average and had been through more than six lifetime episodes.¹⁰ In that group, 39% of patients who received two 25 mg doses had a clinically meaningful improvement on the standard MADRS depression scale by week 6, and that response held through at least week 26.⁹ Almost 30% of those responders went into remission during the treatment period.¹¹

That second dose appears to matter. The single-dose COMP005 trial saw a response rate of about 25%, which suggests a follow-up session may help some patients.¹⁰

Results in major depression

Trials in major depressive disorder, where patients had not necessarily failed other treatments, show even larger effects. In the 2021 Johns Hopkins study, people received two psilocybin sessions along with supportive therapy. By four weeks, 71% had responded and more than half were in remission.³ A year later, most were still doing well.⁶

The 2023 Usona trial, published in JAMA, compared a single dose of psilocybin with niacin, an active placebo that causes flushing so participants could not easily guess their group. Psilocybin produced a significantly larger drop in depression scores that started within days and held through the six-week study.⁷

Not every result is a clean win. When Imperial College compared psilocybin head to head with the SSRI escitalopram over six weeks, the difference on the primary depression score was not statistically significant, although psilocybin looked better on most secondary measures.⁴ Honest reporting of results like this is part of why the field is now taken seriously.

Depression and anxiety with serious illness

Some of the most moving data come from people facing life-threatening cancer. In two 2016 trials at Johns Hopkins and NYU, a single psilocybin session produced substantial reductions in depression and anxiety, along with improvements in quality of life and sense of meaning, and most participants maintained those gains at six months.¹²

What a psilocybin treatment session looks like

Clinical psilocybin therapy is structured and supervised. While protocols vary, most trials follow the same basic arc:

1. Screening. A medical and psychiatric evaluation rules out people at higher risk.
2. Preparation. One or more sessions with the care team to build trust and set expectations.
3. Dosing day. The patient takes a measured dose of synthetic psilocybin in a calm, living-room style space, usually lying down with eyeshades and music. Trained staff stay present for the six to eight hours. In one Compass analysis, almost 80% of session time was spent in silence, with staff offering support rather than directing the experience.¹²
4. Integration. Follow-up visits help the patient make sense of the experience and apply it to daily life.

Side effects and who should not take it

In trials, the most common side effects were headache, nausea, dizziness, and fatigue, usually mild and gone within a day. Blood pressure and heart rate rise temporarily during the session. Some people have frightening or emotionally overwhelming experiences, which is why trained staff are present.

Researchers also watch closely for suicidal thoughts. In the 2022 Compass Phase 2b trial, suicidal ideation or self-injury was reported in all dose groups, including the lowest, which reflects how ill this population is and underlines why treatment happens with monitoring and follow-up care.⁵

Trials generally exclude people with a personal or family history of psychosis or bipolar disorder, recent suicide attempts, or uncontrolled heart conditions. Psilocybin can also interact with medications such as lithium. Self-treating severe depression with mushrooms bought outside a regulated setting carries real risks, including unknown potency and no support if things go wrong.

When will psilocybin be available for depression?

Compass Pathways is submitting its New Drug Application to the FDA on a rolling basis and expects to complete it in Q4 2026. The FDA also selected COMP360 for its Commissioner's National Priority Voucher program, which can shorten the review to roughly one to two months after filing.¹³ The company has said it expects a commercial launch in the first half of 2027, subject to FDA approval and DEA rescheduling.¹⁴

Until then, there are three legal ways to access psilocybin in the U.S.:

• State programs. Oregon and Colorado license psilocybin sessions for adults 21 and older. New Mexico's medical program is expected to begin treating patients around the end of 2026. See where psilocybin therapy is legal.
• Clinical trials. Search active studies at ClinicalTrials.gov.
• Approved alternatives. Esketamine (Spravato) is already FDA approved for treatment-resistant depression and is offered at certified clinics nationwide.

Common questions

Can psilocybin cure depression?

For some people, one or two sessions have led to remission lasting many months. For others, the benefit is partial or fades. Researchers describe it as a promising treatment, not a guaranteed cure, and long-term data on repeat treatment are still coming in.

Can I take psilocybin while on antidepressants?

Talk to your prescriber first. Many trials required participants to taper off antidepressants beforehand, and some medications can blunt or dangerously change psilocybin's effects. Never stop a psychiatric medication on your own.

Does microdosing help depression?

The evidence is weak so far. Placebo-controlled microdosing studies have generally found effects similar to placebo,¹⁵ while the strong trial results above come from full, supervised doses.

Sources

1. Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Journal of Psychopharmacology. 2016. doi.org/10.1177/0269881116675513
2. Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. Journal of Psychopharmacology. 2016. doi.org/10.1177/0269881116675512
3. Davis AK, et al. Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry. 2021. doi.org/10.1001/jamapsychiatry.2020.3285
4. Carhart-Harris R, et al. Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine. 2021. doi.org/10.1056/NEJMoa2032994
5. Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New England Journal of Medicine. 2022. doi.org/10.1056/NEJMoa2206443
6. Gukasyan N, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. Journal of Psychopharmacology. 2022. doi.org/10.1177/02698811211073759
7. Raison CL, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023. doi.org/10.1001/jama.2023.14530
8. Psychiatric Times. New 6-month data from second Phase 3 trial confirms rapid effect of COMP360 for TRD. July 2026. psychiatrictimes.com
9. Compass Pathways. Six month data from second Phase 3 trial confirming rapid and durable profile. July 7, 2026. businesswire.com
10. Tablets & Capsules. Data in hand, Compass psychedelic on track for Q4 NDA submission. July 2026. tabletscapsules.com
11. PharmaTimes. Compass Pathways reports six-month data confirming durable profile of COMP360. July 7, 2026. pharmatimes.com
12. Compass Pathways. Second quarter and first half 2026 financial results and business highlights. August 5, 2026. seekingalpha.com
13. Compass Pathways. FDA granted NDA rolling review request and awarded Commissioner's National Priority Voucher. 2026. Business Wire via Infront
14. Compass Pathways. Q2 2026 results: commercial launch expected in first half of 2027. compasspathways.com (PDF)
15. Szigeti B, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021. doi.org/10.7554/eLife.62878

This article is for education only and is not medical advice. Psilocybin is a Schedule I substance under U.S. federal law and is not FDA approved. If you are struggling with depression, talk with a licensed clinician. In a crisis, call or text 988.